PPARA

Overview

Peroxisome proliferator-activated receptor alpha (PPARα), encoded by the PPARA gene (Wikidata: Q18030677), is a ligand-activated transcription factor belonging to the nuclear receptor superfamily. It is expressed predominantly in tissues with high rates of fatty acid catabolism, including the liver, heart, skeletal muscle, and kidney. Upon activation by endogenous lipid ligands or synthetic agonists such as fibrate-class drugs, PPARα forms a heterodimer with the retinoid X receptor (RXR) and binds to peroxisome proliferator response elements (PPREs) in the promoter regions of target genes, thereby orchestrating the transcriptional programs governing fatty acid uptake, mitochondrial and peroxisomal β-oxidation, ketogenesis, and lipoprotein metabolism. Its central role in maintaining hepatic and systemic lipid homeostasis makes it a high-priority pharmacological target in metabolic liver diseases, dyslipidemia, and related cardiometabolic conditions.

Beyond its canonical lipid-regulatory functions, PPARα intersects with inflammatory signaling, mitochondrial quality control, and oxidative stress response pathways. It operates within a broader metabolic regulatory network alongside complementary nuclear receptors such as PPARG, deacetylases such as sirtuin 1 (SIRT1), and antioxidant transcription factors such as nuclear factor erythroid 2-related factor 2 (NRF2). Dysregulation of PPARα activity has been linked to non-alcoholic and metabolic dysfunction–associated steatotic liver disease (MASLD), diabetic nephropathy, aging-related renal fibrosis, and dyslipidemia, underscoring its broad translational relevance.

Focus of Latest Publications

Recent publications have continued to position PPARA as a central regulator of lipid metabolism, fatty acid oxidation, and hepatoprotection across metabolic and renal disease models. Several studies used PPARA as a mechanistic readout or therapeutic target in steatotic liver disease, hyperlipidemia, hyperuricemia, and crystal-induced kidney injury, with most reports linking increased PPARA activity or expression to improved lipid handling and tissue protection.

In liver disease models, PPARA was repeatedly associated with enhanced fatty acid oxidation and reduced lipid deposition. A study of Aspergillus niger-fermented pine pollen in alcoholic fatty liver disease found that treatment suppressed lipogenesis while upregulating PPARA and CPT1, consistent with improved fatty acid oxidation and reduced hepatic injury. Similarly, a fibrate-like compound, T2, improved serum lipids and liver histology in hyperlipidemic mice and significantly increased PPARA protein expression; molecular docking also supported binding to the PPARA protein site. In metabolic dysfunction-associated steatohepatitis, a new series of tetrazolone derivatives yielded a potent and selective PPARA/PPARD dual agonist, with the lead compound A32 strongly inducing downstream fatty acid oxidation genes including PDK4, CPT1A, and ACADVL in HepG2 cells.

Other studies linked PPARA signaling to broader metabolic benefits. In a hyperuricemia mouse model, biotransformation-derived metabolites from Astragalus membranaceus and Cordyceps militaris lowered uric acid, improved liver and kidney function, and activated hepatic PPARA signaling while also reducing renal urate transporters. In metabolic dysfunction-associated steatotic liver disease, pedunculoside was reported to act through HNRNPA1 and PPARA signaling to enhance mitochondrial fatty acid β-oxidation, further reinforcing the role of PPARA in mitochondrial lipid catabolism.

PPARA was also implicated in disease exacerbation when its lipid-oxidation program was altered in the wrong context. In aged mice with calcium oxalate crystal-induced kidney injury, SIRT1 was shown to regulate worsening mitochondrial dysfunction and fibrosis through PPARA, suggesting that SIRT1-PPARA signaling contributes to age-related susceptibility to renal damage. In another study of nonalcoholic fatty liver disease, cathepsin G promoted hepatic lipid deposition by suppressing genes involved in lipid oxidation, including PPARA, indicating that reduced PPARA-linked oxidation may contribute to steatosis progression.